Changes Come to Genzyme | GenomeWeb

Henri Termeer, the CEO of Genzyme, told the Wall Street Journal's Health Blog last week that he was considering selling some of the company's non-essential business, and this week the company said which ones were for sale: its genetic testing, diagnostics, and pharmaceutical intermediates businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.